Literature DB >> 30982497

PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.

Zhenghua Fei1, Zhenxiang Deng2, Lingyang Zhou3, Kejie Li1, Xiaofang Xia1, Raoying Xie1.   

Abstract

Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma of the head and neck. Cancer therapy targeting programmed cell death protein-1 (PD-1) or programmed death ligand-1 (PD-L1) is revolutionary. However, the tumorigenic mechanism of PD-L1 is not yet clear in NPC. Here we demonstrated an oncogenic role of PD-L1 via activating PI3K/AKT in NPC cells. PD-L1 overexpression was frequently detected in NPC biopsies and cell lines by qRT-PCR. PD-L1 overexpression and knockdown demonstrated that PD-L1 promoted NPC cell invasion and metastasis in vitro and in vivo. Mechanistically, PD-L1 prominently activated the epithelial-mesenchymal transition (EMT) process in a PI3K/AKT-dependent manner. Taken together, we found that PD-L1 overexpression confers NPC cell malignancy and aggressiveness via activating the downstream PI3K/AKT signaling. Thus, these results provide a basis for diagnosis and treatment of NPC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30982497      PMCID: PMC7848446          DOI: 10.3727/096504018X15446984186056

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


INTRODUCTION

Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma of the head and neck. Currently, it is believed that the incidence of NPC is also characterized by ethnic susceptibility, regional concentration, and familial aggregation1. The nasopharynx is more secluded, and the early symptoms are not obvious. Many NPC patients have been diagnosed in the middle and late stages, and the average 5-year survival rate of patients with middle and advanced stage is around 70%2. Therefore, exploring the molecular mechanism of progression and metastasis of NPC and new intervention targets have important clinical significance for improving the cure rate and survival rate of NPC, to prolong patients’ life. Epithelial–mesenchymal transition (EMT) is important for tumor cell invasion and metastasis3. EMT is a particular phenomenon of the epithelial cells transformed into mesenchymal cells in physiological and pathological conditions4. The concept of EMT was developed by Greenberg and Hay in 1982. They found that the epithelial cells formed into mesenchymal cell samples in collagen gel by forming pseudopodia and loss of polarity, obtained stromal cells markers such as N-cadherin, vimentin, and ultimately obtained migration ability5. Invasion and metastasis are significant aggressive phenotypes of human cancers and the most lethal attributes of cancer death. Prevention of tumor invasion and metastasis has attracted great attention in clinical research6–10. Therefore, studying the molecular mechanism of EMT is of great significance to understand the invasion and metastasis of tumors and to develop novel interventional therapy for tumors. In this study, we investigated whether programmed death ligand 1 (PD-L1) was involved in EMT, invasion, and metastasis of NPC, and the underlying mechanisms. Our results showed, for the first time, that PD-L1 triggered EMT-like cellular marker alterations and promoted invasion and metastasis of NPC by activating the PI3K/AKT pathway. Numerous studies have found that PD-L1 is overexpressed in a variety of tumor tissues. Highly expressed PD-L1 interacts with its receptor programmed cell death protein-1 (PD-1), can cause apoptosis and immune disability of tumor antigen-specific T cells, can make tumor cells escape immune surveillance, and can promote tumor occurrence and development11. Antibodies targeting PD-1 or PD-L1 can effectively block the recognition process between PD-1 and PD-L1, and clinical research results have suggested that they have good therapeutic effects on melanoma12, lung cancer13, and kidney cancer14. However, the tumorigenic mechanism of PD-L1 is not yet clear. We found that PD-L1 could promote tumor invasion and metastasis in NPC in our research.

MATERIALS AND METHODS

Tissue Samples

The tissues samples were obtained from patients that did not receive chemoradiotherapy. All participants signed the consent forms before carrying out this research and approval was received from the Human Ethics Committee of Gannan Medical College.

Cell Culture

NPC cell lines (5-8F, 6-10B, CNE1, CNE2, SUNE1, HONE1, C666-1) and normal nasopharyngeal epithelial cells (NP69) were obtained from the Cancer Institute of Southern Medical University (Guangzhou, P.R. China). The authenticity of cell lines in our study was verified with the DNA fingerprinting method. All cell lines used in this study were maintained in RPMI-1640 medium (Invitrogen, Shanghai, P.R. China) with 10% FBS (HyClone, Logan, UT, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen), and were incubated at 5% CO2 at 37°C.

Migration and Invasion Assays

We determined the effect of PD-L1 on NPC cell migration and invasion in vitro by using a traditional Transwell assay/modified Boyden chamber. For Transwell migration assay, 1 × 105 cells were seeded into the upper chamber (BD Biosciences, San Jose, CA, USA) with serum-free DMEM. Boyden invasion assay was performed using Matrigel (BD Biosciences) in the upper chamber. DMEM with 10% FBS was put into the lower compartment as chemoattractant. Cells were allowed to migrate for 12 h. The remaining cells in the upper chamber were scraped out by cotton swap. The cells that had migrated to the lower surface of the membrane were fixed with 100% methanol and stained with hematoxylin solution (Sigma-Aldrich, St. Louis, MO, USA), followed by counting in five random optical fields. The detection procedures were as described in our previous publication10.

RNA Isolation, Reverse Transcription, and Quantitative Real-Time PCR

The TRIzol reagent, iScript cDNA synthesis kit, and SYBR PrimeScript miRNA RT-PCR Kit were purchased from TaKaRa Bio (Dalian, P.R. China). The procedures of RNA isolation, reverse transcription, and qRT-PCR were carried out according to the manufacturer’s protocol and our previous publication15. The primers used to amplify PD-L1 (Invitrogen) were 5′-TGGCATTTGCTGAACGCATTT-3′ (forward) and 5′-TGCAGCCAGGTCTAATTGTTTT-3′ (reverse). The primers used for amplifying E-cadherin (Invitrogen) were 5′-TGCCCAGAAAATGAAAAAGG-3′ (forward) and 5′-GTGTATGTGGCAATGCGTTC-3′ (reverse). The primers used for amplifying vimentin (Invitrogen) were 5′-GAGAACTTTGCCGTTGAAGC-3′ (forward) and 5′-GCTTCCTGTAGGTGGCAATC-3′ (reverse). The primers used for amplifying β-catenin (Invitrogen) were 5′-AGGTCTGAGGAGCAGCTTCA-3′ (forward) and 5′-ATTGTCCACGCTGGATTTTC-3′ (reverse). The primers used for amplifying N-cadherin (Invitrogen) were 5′-ACAGTGGCCACCTACAAAGG-3′ (forward) and 5′-CCGAGATGGGGTTGATAATG-3′ (reverse). The primers used for amplifying GAPDH (Invitrogen) were 5′-ACCCAGAAGACTGTGGATGG-3′ (forward) and 5′-TCTAGACGGCAGGTCAGGTC-3′ (reverse).

Western Blotting

For each sample, 25 μg of total protein extracts was separated on SDS-PAGE gels and transferred to PVDF membranes, which were blocked with 5% BSA for 1 h and incubated with primary antibodies against PD-L1, E-cadherin, vimentin, PI3K, pPI3K, AKT, and pAKT (Cell Signaling Technology, Danvers, MA, USA) and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All the primary antibodies were incubated overnight at 4°C, followed by incubation with corresponding secondary antibody and detection.

Immunohistochemistry

The staining procedure was performed according to manufacturer recommendation protocol and the detailed steps have been described previously15.

In Vivo Metastasis Analysis in Nude Mice

Female BALB/c nude mice (4–5 weeks) were from Wenzhou Medical University and were maintained in microisolator cages under aseptic conditions. For in vivo metastasis assays, the vector- or PD-L1-expressing CNE2 cells (1.0 × 106) were subcapsularly transplanted into the liver of nude mice (eight mice/per group), respectively. All animals were sacrificed on the 30th day. This study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Wenzhou Medical University. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Wenzhou Medical University. Subcapsular transplantation of NPC cells was performed under sodium pentobarbital anesthesia to minimize suffering.

Statistical Analysis

SPSS 16.0 software was used for statistical analysis. Data are presented as means ± SD of at least three independent experiments. The results were analyzed using a two-tailed Student’s t-test. A value of p < 0.05 was considered statistically significant.

RESULTS

PD-L1 Overexpression Was Frequently Detected in NPC Biopsies and Cell Lines

We evaluated the expression of PD-L1 mRNA in 81 NPC biopsies and 20 noncancerous nasopharyngeal epithelial biopsies by qRT-PCR. High expression of PD-L1 was detected in NPC specimens (Fig. 1A). In addition, the overexpression of PD-L1 was found in NPC cell line (5-8F, 6-10B, CNE1, CNE2, SUNE1, HONE1, and C666-1) cells (Fig. 1B). Therefore, PD-L1 overexpression was more frequently detected in NPC than in noncancerous nasopharyngeal epithelial biopsies and NP69 cell line.
Figure 1

The expression of programmed death ligand-1 (PD-L1) in nasopharyngeal carcinoma tissues and cells. (A) PD-L1 was upregulated in nasopharyngeal carcinoma tissues. (B) PD-L1 was upregulated in nasopharyngeal carcinoma cells. *p < 0.05 compared to control.

The expression of programmed death ligand-1 (PD-L1) in nasopharyngeal carcinoma tissues and cells. (A) PD-L1 was upregulated in nasopharyngeal carcinoma tissues. (B) PD-L1 was upregulated in nasopharyngeal carcinoma cells. *p < 0.05 compared to control.

Ectopic Expression of PD-L1 in NPC Cells Induced EMT-Like Molecular Changes and Enhanced Cell Migration and Invasion by Activating the PI3K/AKT Pathway

EMT is a central mechanism contributing to invasion and metastasis of various cancers7,16,17. To understand whether PD-L1 overexpression directly induces EMT, and migration and invasion of NPC cells, we examined the surface markers and phenotypic changes of CNE2 cells with ectopic expression of PD-L1. The PD-L1 transgene was successfully overexpressed in CNE2 cells (Fig. 2D and E). PD-L1-expressing CNE2 cells exhibited typical EMT-like phenotypes (Fig. 2A). Therefore, we also examined the effects of PD-L1 on the migration and invasion of NPC cells based on Transwell migration and Boyden invasion assays. As shown in Figure 2B and C, PD-L1-expressing CNE2 cells displayed significantly enhanced migration and invasion abilities in comparison with vector-expressing cells. The qRT-PCR and Western blotting results demonstrated that ectopic expression of PD-L1 significantly reduced the expression of epithelial markers (i.e., E-cadherin and/or β-catenin) and significantly increased the expression of mesenchymal markers (vimentin and/or N-cadherin) in CNE2 cells (Fig. 2D and E). In mechanism studies, we found that PI3K/AKT signaling contributed most significantly to the upregulation of PD-L1 in NPC cells (Fig. 2F). In order to further determine whether the PI3K/AKT pathway affects alteration of EMT gene in PD-L1-expressing CNE2 cells, a PI3K/AKT inhibitor (LY294002) was used to treat PD-L1-expressing CNE2 cells. The inhibition was specific for PI3K at concentrations up to 20 μM. The results showed that treatment with LY294002 significantly abolished the effect of PD-L1 on migration and invasion (Fig. 2B and C), and EMT gene (Fig. 2D and E). Taken together, these results suggested that PD-L1 overexpression enhanced the migration and invasion of NPC cells in vitro by inducing EMT-like cellular marker alterations via activating the PI3K/AKT signaling pathway.
Figure 2

Enhanced cell migration and invasion in PD-L1-expressing CNE2 cells via the PI3K/AKT pathway. (A) CNE2 cells coupled with an alteration of cellular morphology. (B, C) The migration and invasion were analyzed with an in vitro migration assay using a Transwell chamber and an in vitro invasion assay using a Matrigel-coated Boyden chamber, respectively. PI3K inhibitor (LY294002) abolished the migration and invasion capability induced by PD-L1. Representative photomicrograph is presented. The migrated cells were plotted as the average number of cells per field of view from five different experiments, as described in Materials and Methods. (D, E) The mRNA and protein expressions of EMT-related genes were detected by quantitative real-time (qRT)-PCR and Western blot with PD-L1-overexpression in CNE2 cells and pretreated with LY294002 (20 μM). (F) The protein expressions of PI3K/AKT signal pathway were detected by Western blot. *p < 0.05 compared to control.

Enhanced cell migration and invasion in PD-L1-expressing CNE2 cells via the PI3K/AKT pathway. (A) CNE2 cells coupled with an alteration of cellular morphology. (B, C) The migration and invasion were analyzed with an in vitro migration assay using a Transwell chamber and an in vitro invasion assay using a Matrigel-coated Boyden chamber, respectively. PI3K inhibitor (LY294002) abolished the migration and invasion capability induced by PD-L1. Representative photomicrograph is presented. The migrated cells were plotted as the average number of cells per field of view from five different experiments, as described in Materials and Methods. (D, E) The mRNA and protein expressions of EMT-related genes were detected by quantitative real-time (qRT)-PCR and Western blot with PD-L1-overexpression in CNE2 cells and pretreated with LY294002 (20 μM). (F) The protein expressions of PI3K/AKT signal pathway were detected by Western blot. *p < 0.05 compared to control.

Silence of Endogenous PD-L1 Reversed EMT Gene Change and Reduced the Migration and Invasion Abilities of NPC Cells by Inhibition of the PI3K/AKT Pathway

To further examine the effects of PD-L1 on EMT, and migration and invasion of NPC cells, endogenous PD-L1 in SUNE1 cells was silenced using specific shRNA. The shRNAPD-L1 specifically knocked down endogenous PD-L1 mRNA (Fig. 3C) and protein (Fig. 3D) expression in SUNE1 cells. Transwell migration and Boyden invasion assays also demonstrated that knockdown of endogenous PD-L1 by shRNA markedly inhibited the migration and invasion of SUNE1 cells (Fig. 3A and B). As indicated in Figure 3C and D, silencing endogenous PD-L1 in SUNE1 cells increased the expression of epithelial markers (i.e., E-cadherin and/or β-catenin) and concomitantly reduced the expression of mesenchymal markers (i.e., vimentin and/or N-cadherin) at both mRNA and protein levels. In addition, PI3K/AKT signal transduction was suppressed by PD-L1 inhibition (Fig. 3E). In order to further determine whether the PI3K/AKT pathway affects alteration of EMT gene in shRNAPD-L1 SUNE1 cells, LY294002 was used to treat shRNAPD-L1 SUNE1 cells. Relative migration and invasion (Fig. 3A and B) as well as expression levels of mesenchymal markers (i.e., vimentin and/or N-cadherin) were decreased by LY294002 relative to the shRNAPD-L1group. Moreover, the effects of pretreatment with LY294002 on shRNAPD-L1 SUNE1 cells increased the expression of epithelial markers (i.e., E-cadherin and/or β-catenin) (Fig. 3C and D). Taken together, suppression of endogenous PD-L1 expression in NPC cells reversed the EMT-like molecular changes and reduced the migration and invasion of NPC cells by inhibiting the PI3K/AKT signal pathway.
Figure 3

Underexpression of PD-L1 decreases cell migration and invasiveness in SUNE1 cells via the PI3K/AKT pathway. (A, B) The migration and invasion were analyzed with an in vitro migration assay using a Transwell chamber and an in vitro invasion assay using a Matrigel-coated Boyden chamber, respectively. The migrated cells were plotted as the average number of cells per field of view from five different experiments, as described in Materials and Methods. (C, D) The mRNA and protein expressions of EMT-related genes were detected by qRT-PCR and Western blot when interfering with PD-L1 expression in SUNE1 cells and pretreated with LY294002 (20 μM). (E) The protein expressions of PI3K/AKT signal pathway were detected by Western blot. *p < 0.05 compared to control.

Underexpression of PD-L1 decreases cell migration and invasiveness in SUNE1 cells via the PI3K/AKT pathway. (A, B) The migration and invasion were analyzed with an in vitro migration assay using a Transwell chamber and an in vitro invasion assay using a Matrigel-coated Boyden chamber, respectively. The migrated cells were plotted as the average number of cells per field of view from five different experiments, as described in Materials and Methods. (C, D) The mRNA and protein expressions of EMT-related genes were detected by qRT-PCR and Western blot when interfering with PD-L1 expression in SUNE1 cells and pretreated with LY294002 (20 μM). (E) The protein expressions of PI3K/AKT signal pathway were detected by Western blot. *p < 0.05 compared to control.

PD-L1 Positively Modulates the Metastasis of NPC Cells In Vivo

Local invasion and distant metastasis are common clinical features of NPC. To determine whether PD-L1 improves the migration and invasion of NPC cells in vivo, the vector- or PD-L1-expressing CNE2 cells were subcapsularly transplanted into the liver of nude mice and formed tumors in the liver. We found that the size of tumors on the liver surface derived from PD-L1-expressing CNE2 cells was significantly larger than that derived from vector-expressing CNE2 cells (Fig. 4A). Moreover, qRT-PCR and IHC analysis revealed that PD-L1 expression of primary tumors derived from PD-L1-expressing CNE2 cells was significantly higher than that of primary tumors derived from vector-expressing CNE2 cell (Fig. 4B and C). In addition, we detected the expression of epithelial markers (i.e., E-cadherin and/or β-catenin) and mesenchymal markers (vimentin and/or N-cadherin) by qRT-PCR and IHC in primary tumors. The results revealed that ectopic expression of PD-L1 CNE2 cells exhibited typical EMT-like phenotypes, including downregulation of epithelial marker E-cadherin and upregulation of mesenchymal marker vimentin (Fig. 4B and C). Thus, PD-L1 positively regulates the metastasis of NPC cells in vivo.
Figure 4

Enforced expression of PD-L1 in CNE2 cells promoted metastasis in vivo. (A) Representative livers from nude mice 30 days after subcapsular liver transplantation of vector-expressing (LV-con) or PD-L1-expressing (LV-PD-L1) CNE2 cells (eight mice/group). (B, C) The expression of PD-L1 and EMT-related genes was detected in tumor tissues by qRT-PCR and immunohistochemistry. *p < 0.05 compared to control.

Enforced expression of PD-L1 in CNE2 cells promoted metastasis in vivo. (A) Representative livers from nude mice 30 days after subcapsular liver transplantation of vector-expressing (LV-con) or PD-L1-expressing (LV-PD-L1) CNE2 cells (eight mice/group). (B, C) The expression of PD-L1 and EMT-related genes was detected in tumor tissues by qRT-PCR and immunohistochemistry. *p < 0.05 compared to control.

DISCUSSION

Current studies have shown that PD-L1 expression is closely related to tumor prognosis. In a previous PD-L1 study, Shi et al.18 found that high PD-L1 expression was associated with TNM stage and prognosis in tumor cells of colorectal cancer patients. Karim et al.19 found that PD-L1 expression in cervical cancer tissues was expressed in a few samples and affected the prognosis of patients. Nomi et al.20 found that PD-L1+ patients with pancreatic cancer had worse prognosis than negative patients. Muenst et al.21 found that the expression of PD-L1 in breast cancer tissues was related to tumor size, pathological classification, and lymph node metastasis, and the total survival time of positive patients was significantly shortened. Frigola et al.22 and Thompson et al.23 found that PD-L1 expression was associated with tumor staging and prognosis in renal cancer patients. Azuma et al.24 found that high expression of PD-L1 in tumor cells of non-small cell lung cancer was associated with EGFR mutation and had a poor prognosis. In addition, relevant studies also showed that PD-L1 expression was high in the cancer tissues of patients with ovarian cancer25, malignant melanoma26, and esophageal cancer27, and the prognosis was poor. Therefore, PD-L1 has been proven to be a poor prognostic factor. We, for the first time, have proved that PD-L1+ expression is closely related to EMT in NPC. PD-L1 may have important significance in the malignant progress of NPC, and blocking PD-L1 and its receptor can improve the clinical outcome of cancer treatment. In the immune response mechanism of the tumor microenvironment, PD-L1 is a negative regulatory molecule, though it can combine with PD-1 by inhibiting T-cell proliferation and promoting cell secretion immunosuppressive factor12. In patients with renal cell carcinoma, those with high expression of PD-L1 are four times more likely to metastasize and die than those with negative PD-L123. These studies and this current study suggest that PD-L1 has a general promotion effect on the occurrence and development of different types of tumors. Although studies have shown that PD-L1 has poor prognosis in NPC28, few studies have revealed the molecular mechanism of PD-L1 expression in NPC cells.
  27 in total

Review 1.  New signals from the invasive front.

Authors:  Gerhard Christofori
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 2.  Complex networks orchestrate epithelial-mesenchymal transitions.

Authors:  Jean Paul Thiery; Jonathan P Sleeman
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

3.  Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.

Authors:  Yuichiro Ohigashi; Masayuki Sho; Yukishige Yamada; Yoshikazu Tsurui; Kaoru Hamada; Naoya Ikeda; Takashi Mizuno; Ryo Yoriki; Hisanori Kashizuka; Katsunari Yane; Fumihiko Tsushima; Noriko Otsuki; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.

Authors:  Ryosuke Hino; Kenji Kabashima; Yu Kato; Hiroaki Yagi; Motonobu Nakamura; Tasuku Honjo; Taku Okazaki; Yoshiki Tokura
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

5.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

6.  Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.

Authors:  Rezaul Karim; Ekaterina S Jordanova; Sytse J Piersma; Gemma G Kenter; Lieping Chen; Judith M Boer; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

7.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 8.  EMT, the cytoskeleton, and cancer cell invasion.

Authors:  Mahmut Yilmaz; Gerhard Christofori
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

Review 9.  Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development.

Authors:  Anne Vincent-Salomon; Jean Paul Thiery
Journal:  Breast Cancer Res       Date:  2003-02-03       Impact factor: 6.466

10.  Targeted Disruption of miR-17-92 Impairs Mouse Spermatogenesis by Activating mTOR Signaling Pathway.

Authors:  Raoying Xie; Xiaolin Lin; Tao Du; Kang Xu; Hongfen Shen; Fang Wei; Weichao Hao; Taoyan Lin; Xia Lin; Yujuan Qin; Huiyan Wang; Lin Chen; Sheng Yang; Jie Yang; Xiaoxiang Rong; Kaitai Yao; Dong Xiao; Junshuang Jia; Yan Sun
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more
  10 in total

Review 1.  Programmed death ligand 1 signals in cancer cells.

Authors:  Anand V R Kornepati; Ratna K Vadlamudi; Tyler J Curiel
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 60.716

Review 2.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

3.  Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity.

Authors:  Pedram Yadollahi; You-Kyoung Jeon; Wooi Loon Ng; Inhak Choi
Journal:  BMB Rep       Date:  2021-01       Impact factor: 4.778

4.  Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.

Authors:  Chen Zhang; Qing Yang
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

5.  Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor.

Authors:  Feiyu Shan; Leitao Sun; Leyin Zhang; Kaibo Guo; Qingying Yan; Guan Feng; Ying Zhu; Minhe Shen; Shanming Ruan
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

6.  Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.

Authors:  Mingjing Peng; Songqing Fan; Junjun Li; Xiao Zhou; Qianjin Liao; Faqing Tang; Wei Liu
Journal:  Genes Nutr       Date:  2022-02-14       Impact factor: 5.523

Review 7.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

8.  STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer.

Authors:  J Chen; Y Liu; Y Zhu; Y Chen; J Feng; T Jiang; X Zheng; L Chen; J Jiang
Journal:  Clin Transl Oncol       Date:  2022-02-02       Impact factor: 3.340

9.  Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.

Authors:  Qian Zhu; Ai-Lin Zhong; Hao Hu; Jing-Jing Zhao; De-Sheng Weng; Yan Tang; Qiu-Zhong Pan; Zi-Qi Zhou; Meng-Jia Song; Jie-Ying Yang; Jun-Yi He; Yuan Liu; Min Li; Wan-Ming Hu; Chao-Pin Yang; Tong Xiang; Ming-Yuan Chen; Gang Ma; Ling Guo; Jian-Chuan Xia
Journal:  J Hematol Oncol       Date:  2020-01-03       Impact factor: 17.388

10.  Radiation induces epithelial to mesenchymal transition via upregulation of PD-L1 in nasopharyngeal carcinoma cell.

Authors:  Heming Li; Zhi Wang; Shanshan Liang; Qiuge Liu; Piao Wang; Longyu Cai; Ruoyu Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.